Example collocations logo

Vaccine in sentence

824 examples of Vaccine in a sentence

Since 2001, there have been no fewer than 140 new vaccine launches in Africa, thanks to local leadership and support from my organization, the GAVI Alliance, and its partners, UNICEF, the World Health Organization, the World Bank, and the Bill and Melinda Gates Foundation.
A vaccine, first used in humans in 1921, is still in use around the world today.
Developing a more effective vaccine would have the biggest impact on the epidemic.
The Bacillus Calmette–Guérin vaccine is given to infants in many parts of the world, but its efficacy against pulmonary TB is highly variable.
To eliminate the disease globally, a better vaccine would be crucial.
By developing new tools – including rapid diagnostics, safe and shorter treatment of TB infection and disease, and an efficacious TB vaccine – strengthening health systems, and improving the living conditions of at-risk populations, we can neutralize one of humankind’s oldest killers.
This approach, whereby computational analysis of a pathogen’s genome enables identification and screening of a great many more potential vaccine targets than was previously possible, was used in the successful development of a vaccine against meningitis B.The past decade has already yielded major advances in structure-assisted vaccine discovery, synthetic biology, systems biology, and immune monitoring.
Such a project would represent a paradigm shift in vaccine development.
The current process is long (often spanning decades from concept to licensure), has a low probability of success (because of the limitations of animal models in predicting immune response and efficacy in humans), and is costly (often requiring hundreds of millions of dollars to develop a single vaccine).
Investing that amount over the next decade in a coordinated effort to address the major questions facing vaccine development would rapidly accelerate our search for effective solutions, implying a transformative impact on individual and public health.
Using recent advances, however, scientists have now identified highly conserved regions of this variable virus, determined their molecular structure, and begun designing next-generation vaccine candidates to elicit antibodies that target these regions to prevent HIV infection.
But HIV vaccine development, like that for several other diseases, is still impeded by the limitations of what animal models can tell us about how to elicit the necessary immune responses in humans.
Two recent advances could accelerate vaccine development and reduce its costs dramatically.
Models show that adding even a partly effective AIDS vaccine to the current range of prevention and treatment procedures could dramatically lower the rate of HIV infection.
Today, technological advances in vaccine discovery and immune monitoring allow us realistically to explore this potentially game-changing approach to disease prevention.
A vaccine against hepatitis B virus is proving to be effective in reducing the incidence of liver cancer.
The Tdap vaccine, which protects adults from diphtheria, tetanus, and pertussis, could reduce this burden considerably.
Another vaccine, called Td, protects against tetanus and diphtheria, but not pertussis.
Two main types of pneumococcal vaccine available for older adults – the 23-valent pneumococcal polysaccharide vaccine (PPV23) and the pneumococcal conjugate vaccine (PCV13) – could ameliorate the situation.
The expanded funding allowed major campaigns against AIDS, TB, and malaria; a major scaling up of safe childbirth; and increased vaccine coverage, including the near-eradication of polio.
The key to this tremendous medical achievement was not, as one might expect, some major health breakthrough (the smallpox vaccine had been around since the eighteenth century).
That is why WHO delegates debated for days before agreeing, by the slimmest margin ever, to provide a measly $2.4 million per year for the effort – too little to cover the costs of whatever vaccine was not donated, let alone fund the necessary logistical support.
Henderson recognized that the Soviet Union – which had been pressing for an eradication campaign for several years, and had already pledged to donate 25 million doses of vaccine annually – would not be enthusiastic about an American leading the charge.
So he reached out to the Soviet deputy health minister, Dimitri Venediktov, with whom he established a rapport that enabled the two sides to work together on strategy and logistics, in addition to their vaccine donations (the US had agreed to provide 50 million doses each year).
What COVID Is Costing WomenNEW HAVEN – Although COVID-19 infections and deaths are surging in many parts of the world, recent announcements of apparently successful vaccine trials have offered a light at the end of the tunnel.
The most efficient way to bring this crisis to an end – possibly as early as next year – is with a safe and effective vaccine, manufactured in large quantities and distributed globally.
Created by Gavi, the Vaccine Alliance, the World Health Organization, and the Coalition for Epidemic Preparedness Innovations, this innovative platform aims to distribute at least two billion doses of COVID-19 vaccine by the end of 2021.
As it stands, over 160 vaccine candidates are in preclinical or clinical development.
The problem is that governments may feel compelled to eschew cooperation, in favor of negotiating directly with vaccine manufacturers to claim the doses they need.
Even if a government secures enough doses of an effective vaccine for its own population, some of its people – such as those who are immunocompromised and may not be able to be vaccinated – would be left exposed if other countries are unable to obtain enough vaccine.
BackNext